AALL2121: SNDX-5613 for Relapsed or Refractory Leukemia

AALL2121: SNDX-5613 for Relapsed or Refractory Leukemia

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description

This study enrolls patients that have been diagnosed with acute leukemia associated with a KMT2A (MLL) gene rearrangement (referred to as KMT2Arearranged, or KMT2A-R). The KMT2A-R leukemia has come back after treatment (relapsed) or is not responding to treatment (it is refractory). This study involves taking a study drug called SNDX-5613. The study is divided into two phases: one in which the study drug is given in combination with chemotherapy and a phase where the study drug is given alone. The purpose of the study is to test the safety of the study drug with chemotherapy, and how well the treatment regimen works for infants and young children with relapsed or refractory KMT2A-R leukemia.

What to expect
As a participant in the research, you will: Depending on which phase you enroll into, you will either receive a study drug called SNDX-5613 OR receive a study drug called SNDX-5613 in addition to chemotherapy you would receive as part of your regular cancer careComplete frequent clinic visits at CHOP Have a bone marrow evaluationHave frequent blood testsHave extra or leftover bone marrow collected if you have bone marrow samples collected as part of your regular cancer careComplete medication diariesHave periodic electrocardiograms (ECGs) and echocardiograms (ECHOs) as part of your regular cancer care
Have periodic imaging performed as part of your regular cancer care to evaluate your response to treatment

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.